Geode Capital Management LLC Decreases Stake in Renovaro Inc. (NASDAQ:RENB)

Geode Capital Management LLC cut its holdings in shares of Renovaro Inc. (NASDAQ:RENB) by 9.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,572,290 shares of the company’s stock after selling 155,995 shares during the quarter. Geode Capital Management LLC owned about 0.97% of Renovaro worth $760,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of RENB. Bank of New York Mellon Corp acquired a new stake in shares of Renovaro in the second quarter valued at approximately $220,000. State Street Corp grew its holdings in Renovaro by 3.8% in the 3rd quarter. State Street Corp now owns 1,323,832 shares of the company’s stock valued at $640,000 after buying an additional 48,114 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Renovaro in the 2nd quarter worth $79,000. Finally, Barclays PLC lifted its stake in shares of Renovaro by 315.7% in the 3rd quarter. Barclays PLC now owns 69,531 shares of the company’s stock valued at $34,000 after purchasing an additional 52,804 shares during the last quarter. Hedge funds and other institutional investors own 71.41% of the company’s stock.

Renovaro Trading Down 5.0 %

Shares of NASDAQ:RENB opened at $0.79 on Friday. The business has a 50-day moving average price of $0.97 and a 200 day moving average price of $0.87. Renovaro Inc. has a 12-month low of $0.40 and a 12-month high of $5.25. The company has a market capitalization of $125.77 million, a price-to-earnings ratio of -0.83 and a beta of 0.65.

Renovaro (NASDAQ:RENB) last released its quarterly earnings results on Thursday, October 10th. The company reported ($0.45) earnings per share (EPS) for the quarter.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.